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The rationale for utilizing plant cell culture for production in the pharmaceuti-
cal industry can be exemplified by the realities faced in TAXOL® development.
Such a case study provides the justification for Bristol-Myers Squibb’s (BMS)
investment of well over $10 million to develop this technology to the scale of
commercial production. BMS believes that other products will follow for plant
cell culture and that other new production technologies will be developed as
the need and opportunity are identified for high value products.
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Why Plant Cell Culture for Pharmaceuticals?
¥ Historical success and future promise of natural products as
therapeutics
¥ Increasing constraints on bioprospecting and wild biomass
collection
¥ Emerging technologies increase utility as research tool and
feasibility for commercial use
¥ IdentiÞcation of high-value products with supply problems
Why plant cell culture in the pharmaceutical industry? You are familiar with
the historical successes and what we hope is the future promise of natural prod-
ucts with therapeutic applications. The pharmaceutical industry realizes that
there are increasing constraints on bioprospecting, as well as the collection of
wild biomass for production of natural product-based therapeutics. There are
many emerging technologies, some of which David Evans described earlier, that
have inspired people to use plant cell cultures as a research tool for drug dis-
covery, whether from direct isolation, biotransformation, or directed fermenta-
tions. BMS is the first to look at cell culture for commercial production of a
large, complex therapeutic molecule because of its high value and supply prob-
lem. The compound is paclitaxel; the active ingredient in the product, TAXOL®.
This product alone motivated a large pharmaceutical company with massive
investments in all kinds of production facilities to turn to plant cell culture —
a recent scientific development with little practical application.
A more in-depth look at the four reasons for using cell culture in the
pharmaceutical industry reveals that the full potential of natural products
in medicine has not been realized.
Seventy-five percent of the world’s population depends almost entirely on
plants to treat illness and disease. Historically, 25 percent, and now somewhat
less, of the U.S. pharmaceutical market has been based on plant-derived com-
pounds. There are the older remedies such as digitalis, but also state-of-the-art
drugs like TAXOL®. Very few of the two or three hundred species of plants have
been specifically evaluated for their therapeutic benefit, and the compounds
that have been derived are very novel, diverse, and complex. There are, un-
doubtedly, many more plant-derived compounds of medicinal value to be
identified. However, one important question arises: “Can the continued tradi-
tional screening of plant materials economically compete with new combinatorial
chemistry approaches?” The answer is not yet in, but many are betting on a
combination of the two technologies.
Success and Promise of Natural Products
¥ 75% of world population relies on plants for treating illness/
disease
¥ 25% of U.S. pharmaceutical market from plant-derived
compounds, including state-of-the-art drugs, e.g. TAXOL¤
¥ Only 2% of the >250,000 plant species have been extensively
evaluated as therapeutics
¥ Unparalleled diversity of complex, novel molecular structures
Constraints on Bioprospecting
¥ Geo-political impediments to access
¥ DifÞculty of reliable resupply
¥ Unrealistic expectations of many source countries
¥ Development vs. preservation of biodiversity, disappearance
of rainforest, extinction of many species
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The constraints on bioprospecting are many, (see Figure 3). BMS and many
other companies have screened natural products for many years. We have all
experienced the increasing geopolitical impediments to accessing new biomass
for screening. This is because of the difficulties of prospecting in countries with
underdeveloped scientific infrastructure, less stable governments, or other
constraints. The need for resupply after an interesting compound is identified
may follow years after acquisition of the original plant material. Scientific or
government personnel changes may have occurred, and access for resupply is
sometimes denied or impossible to accomplish. Many source countries have
unrealistic expectations. Plants and their genetic material have been viewed
as “green gold.” Many countries believe bioprospecting within their borders
offers a rare opportunity for economic development in a context of limited
possibilities. This view is unrealistic based on the potential discovery of a single
pharmaceutical product after 3-5 years of screening and another 10 years of
high risk development by the pharmaceutical company. In addition, there is the
need to balance the problem of disappearing rain forests and extinction of many
plant species with the need for development in source countries. As seen in
Figure 4, many technologies, from emerging genetic-engineering possibilities
to evolutionary improvements in standard research techniques, have been used
to increase the utility of cell culture at any scale.
Emerging Technologies
¥ Transgenic plants proteins (Abs, insulin)
Ñ Agrobacterium spp vectors
Ñ ÒGene GunÓ technology
¥ Improvements in analytical chemistry, robotics, and Òmicro
researchÓ
¥ Improvements in bioreactor design for enhanced mass
transfer
The last underlying reason for cell culture in the pharmaceutical industry is
identification of a high value product with limited options for facile commercial
production. TAXOL® clearly fits into this category.
High Value Products/Supply Problem
¥ SkikoninÑnaphthoquinone for skin ailments and as a dye in
cosmetic and silk industry
¥ Paclitaxel (TAXOL¤)
Ñditerpenoid for cancer therapy
TAXOL® was identified over 30 years ago by the National Cancer Institute
(NCI). They found the compound to be a drug with exciting potential for
cancer therapy, but sufficient quantities for development hindered its progress
for decades.
In the early 1960’s, an extract of Pacific yew bark was found to contain very
low concentrations of the active material. In addition, supply of the bark was
extremely limited. It wasn’t until 1971, prompted by this limited supply, that
Dr. Monroe Wall isolated and determined the structure of TAXOL®. In 1979,
Susan Horovitz identified that paclitaxel killed cancer cells in a unique way, by
binding to tubulin. Paclitaxel’s novel structure and unique mechanism of action
made it a high priority for clinical trials by the NCI.
The progress of the clinical trials was extremely slow because only 0.5
kilogram was produced over two years. Although trials were started in 1983,
it took until 1989 to demonstrate clinical activity in solid tumors. The first
success was with refractory ovarian cancer. The NCI wanted to proceed, but
needed a partner to further develop the drug. A competition was held to
determine who in the private sector could best develop the drug. Bristol-Myers
Squibb won the competition and then established cooperative agreements with
multiple government agencies, not a trivial task, to continue development.
The USDA’s Forest Service and the Interior Department’s Bureau of Land
Management assisted in an extensive bark collection program in the Pacific
Northwest — mostly in large areas of Washington, Oregon, and Idaho. The
government agencies developed plans to harvest the bark in a responsible way,
to transfer the bark to BMS, and to minimize the impact on the environment
of this huge collection to assure that the yew tree was not threatened. Bristol-
Myers Squibb paid for all those activities, bought the bark, and managed
the bark collection contract with Hauser Chemical Company. No one had
experience with such a large collection effort, but it was well worth the effort
since the drug was made available to the NCI for vastly expanded clinical trials
within a few months.
TAXOL¤
Pre-CRADA TAXOL® Development
1964 Anticancer activity of PaciÞc yew bark extract noted
1971 Isolation and purification reported
1979 Unique mechanism of action described
1983 Clinical trials initiated
1989 Activity in refractory ovarian cancer reported
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The Pacific yew tree, Taxus brevifolia, is a small, scrubby-looking, extremely
slow-growing tree. Very little was known about it — whether it existed and
how many there were. The tree was considered a nuisance shrub by timber
companies harvesting high-value timber like Douglas Fir. Fortunately, from
spring to fall the bark of the Pacific yew was easily peeled by hand from the
trunk and major limbs of the tree. Up to 1,000 people were in the woods
harvesting bark from 1991- 1993. The Forest Service issued a permit for each
collection bag and policed the effort closely. There was quite a bureaucracy
associated with this collection and the prevention of theft. The bark was taken
to collection centers where it was ground to a workable size, further milled,
either dried in the sun or in low temperature tumblers, and then packed in
large wooden boxes and trucked to Colorado to be chemically extracted. This
process was a low-tech but high brute-force effort. It was an inefficient process,
with uncontrollable quality of the raw materials, but at the time it was the only
possible production process and it worked to the benefit of U.S. public health.
An alternative source was needed as quickly as possible, so BMS immediately
established the multifaceted research program outlined in the following figure.
TAXOL¤
Cooperative Agreements
¥ Government AgenciesÑto develop annual plans, oversee
bark transfer, and ecosystem research/conservation studies
¥ BSMÑpay all government expenses, buy bark, and administer
bark collection contract
Bristol-Myers Squibb
for NCI/DHHS
Forest Service Bureau of Land
for USDA Management
for USDI
Together with the Weyerhauser Paper Products Company, several yew tree
plantations were established that served two purposes — research for
determination of the best cultivar for future plantations, and development of
the best methods to cultivate the huge amounts of biomass that would be
necessary for commercial supply. Prior to reaching these objectives, BMS had 12
million yew trees planted as a commercial source of biomass. The research
effort with Weyerhauser used tens of thousands of clippings collected from
ornamental nurseries all over the United States. They were hand-planted and
cultivated for months in huge greenhouses built specifically for this purpose so
that all growing conditions could be completely controlled. The plants were
transferred to nurseries to acclimate them to the outdoors and then grown in
commercial-scale nurseries. They were grown for three to five years before
harvest. The initial idea was to harvest the entire plant and process it to extract
either the core of the paclitaxel molecule or the intact product. But, it turned
out that the important precursor 10 deacetyl baccatin III (10 DAB) was much
more readily and economically available from Taxus baccata, which grows in
Europe and Asia, than from the North American Taxus species. Therefore,
commercial supplies of 10 DAB were produced in Europe for use by BMS.
Years earlier the company had licensed a process to attach the precursor 10
DAB to the active side chain, and semisynthesis proved to be a commercially
viable option. The renewable biomass, originally gathered in the wild in Europe
and Asia, but now cultivated in Italy, is extracted and the purified 10 DAB is
shipped to Ireland where the side chain addition occurs. The purified bulk
paclitaxel is then shipped to Puerto Rico for formulation and the product,
TAXOL®, is shipped to our distribution centers worldwide.
TAXOL¤
Alternative Sourcing Research
¥ Yew plantations
Ñ R&D to determine best cultivar and conditions
Ñ Cultivation of biomass for commercial supply
¥ Renewable biomass (clippings)
Ñ Precursor isolation/semi-synthesis
Ñ Direct isolation of paclitaxel
¥ Plant cell culture
¥ Total synthesis ?
¥ Other ??
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While the above process is much more efficient and controllable than bark
extraction, the vagaries of weather can still have a significant impact on total
production and quality of the raw materials.
The plant cell culture option was brought to the attention of BMS by a small
company, Phyton Catalytic. This company had been interested in developing
plant cell culture specifically for the production of paclitaxel for several years.
BMS agreed to sponsor their research and licensed the technology as a possible
method of production.
Might the BMS collaboration with Phyton on plant culture provide an even
better process? We believe the answer will be yes. Although a great deal of
research has been accomplished, much development remains. Tens of thou-
sands of yew tree explants were grown on solid nutrient media until calluses
were developed. Small flask suspension cultures were used to select and deter-
mine optional growth parameters for high producing cell lines. Further research
was done in the bench top scale bioreactor where it was determined quickly
that paclitaxel produced in cell culture had fewer impurities than that isolated
from bark and needle extracts. In addition, cell lines could be selected to
produce a specific Taxane of interest.
The potential advantages of cell culture production of paclitaxel emerged
quickly and can be generalized to other fermentations as well.
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Plant cell culture is a more environmentally benign process and produces
product faster than cultivation of biomass. It is a controlled, reliable source
of high-quality material and production levels can be matched to commercial
demand. The cell culture conditions are more easily controlled to assure the
fermentation of the product of choice and its high quality. Downstream pro-
cessing for isolation and purification of the desired product often can be simpli-
fied. This may translate into lower costs, but that has not yet been established.
Cell culture provides the opportunity for additional novel metabolites to be
identified that may have a broader spectrum of activity or an increased potency.
These interesting possibilities have been recognized by major pharmaceutical
companies other than BMS. For example, Merck and Pfizer are using cell
culture for discovery of new or improved medicinal compounds, and new
companies, such as Phytera, are being formed specifically for this purpose.
Today, in Arensburgh, Germany, Phyton operates the world’s largest dedicated
plant cell culture facility. There are cascades of fermentors from 75 to 75,000
liters, and the facility is currently being modified to comply with Good Manu-
facturing Process regulations required for production of human pharmaceu-
ticals. BMS and Phyton continue to collaborate on scaling up the fermentation
of new Taxus sp. cell lines and to develop an optimized isolation and recovery
process.
Today, TAXOL® is approved for use in the therapy of both breast and ovarian
cancer. New, improved treatment schedules have been developed and approved
for use. The semisynthetic method for manufacturing the drug is approved and
TAXOL® is currently in use in more than 50 countries worldwide. Another
major market, Japan, should clear the product for marketing in 1997.
Advantages of Plant Cell Culture
¥ Environmentally benign
¥ Faster growth compared to plants
¥ Controlled, reliable supply of high quality bulk
¥ Quick response to variability in demand
¥ Culture conditions controlled easily
¥ Simplified downstream processing
¥ Novel metabolites
BMS expects the need to increase somewhat as the clinical research program
defines new uses for the drug. The company is confident, however, in its ability
to meet all patent and market demand for TAXOL®. New efficiencies will be
implemented in the semisynthetic process, as well as full development and
commercialization of plant cell culture within a few years.
TAXOL® is an exciting product, which in addition to offering clinical benefit
to hundreds of thousands of patients, has been the sole justification for com-
mercial development of an important technology that was little more than a
laboratory curiosity for decades.
TAXOL¤ Bristol-Myers Squibb
Regulatory Status
¥ U.S. FDA approvals
12/92 ovarian cancer
4/94 breast cancer
6/94 improved dosage regimen
10/94 semisynthetic manufacturing process
¥ Approved in over 50 countries worldwide
